The Potential of ALLO-715 in Relapsed/Refractory Multiple Myeloma: Doris Hansen, MD
The hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.
This content originally appeared on our sister site, OncLive.
ALLO-715 is an allogeneic, off-the-shelf, novel CAR T-cell therapy directed toward BCMA. The approach offers advantages over autologous CAR T-cell therapies such as mitigating manufacturing challenges encountered with the autologous approach.
Hansen discussed how many patients with relapsed/refractory multiple myeloma experience disease progression during the period required for autologous CAR T-cell therapy generation. This is an area that allogeneic products are also advantageous as patients can receive their ALLO-715 infusion within a period of 5 days.
Initial findings from the ongoing phase 1 UNIVERSAL trial (NCT04093596) demonstrated an overall response rate of 60% with a 320 x 106 dose of CAR cells in 6 patients with relapsed/refractory multiple myeloma. Four patients treated at this dose level achieved at least a very good partial response and minimal residual disease negativity.
On April 21, 2021, the FDA granted ALLO-715 a Regenerative Medicine Advanced Therapy designation as a potential treatment for patients with relapsed/refractory multiple myeloma.
